Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.

Abstract:

BACKGROUND:We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS:We queried the Cryo On-Line Database registry for men who had undergone SFC and STC of the prostate for RT-persistent or recurrent disease. Propensity score weighting was used to match age at treatment, presalvage therapy prostate-specific antigen level, Gleason sum, and presalvage cryotherapy androgen deprivation therapy status. The primary outcome was progression-free survival. RESULTS:A total of 385 men with biopsy-proven persistent or recurrent prostate cancer after primary RT were included in the present study. The median follow-up, age, prostate-specific antigen, and Gleason sum before salvage cryotherapy was 24.4 months (first and third quartile, 9.8 and 60.3), 70 years (first and third quartile, 66 and 74 years), 4 ng/dL (first and third quartile, 2.7 and 5.6 ng/dL), and 7 (first and third quartile, 6 and 8), respectively. After propensity score weighting, the difference in progression-free survival was not statistically significant between the patients who had undergone STC and those who had undergone SFC (79.8% vs. 76.98%; P = .11 on weighted log-rank test). SFC was associated with a lower probability of post-treatment transient urinary retention (5.6% vs. 22.4%; P < .001). No significant differences were found in the incidence of rectal fistula (1.4% vs. 3.8; P = .30), new-onset urinary incontinence within 12 months (9.3% vs. 15.1%; P = .19), or new-onset erectile dysfunction within 12 months (52.6% vs. 59.6%; P = .47) between the SFC and STC groups, respectively. CONCLUSIONS:STC resulted in similar 2-year oncologic outcomes compared with SFC in the RT-persistent/recurrent disease population. However, the patients who had undergone SFC had a lower urinary retention rate compared with those who had undergone STC.

journal_name

Clin Genitourin Cancer

authors

Tan WP,ElShafei A,Aminsharifi A,Khalifa AO,Polascik TJ

doi

10.1016/j.clgc.2019.11.009

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

e260-e265

issue

3

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(19)30360-X

journal_volume

18

pub_type

杂志文章
  • Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

    abstract:BACKGROUND:We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS:A retrospective analysis of data from 5714 patients with mRCC t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.06.005

    authors: Tannir NM,Figlin RA,Gore ME,Michaelson MD,Motzer RJ,Porta C,Rini BI,Hoang C,Lin X,Escudier B

    更新日期:2017-06-20 00:00:00

  • Baseline serum 25-hydroxyvitamin d levels in men undergoing radical prostatectomy: is there an association with adverse pathologic features?

    abstract:INTRODUCTION/BACKGROUND:The purpose of this study was to evaluate the prevalence of vitamin D (VitD) deficiency in men undergoing radical prostatectomy and determine whether an association exists between preoperative VitD levels and adverse pathologic features. PATIENTS AND METHODS:Patients scheduled to undergo radica...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.02.004

    authors: Berg WT,Shapiro EY,Rothberg MB,Bergman A,Scarberry K,Wambi C,Patel T,Badani KK

    更新日期:2014-10-01 00:00:00

  • Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

    abstract:PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2017.10.004

    authors: Chipollini J,Abel EJ,Peyton CC,Boulware DC,Karam JA,Margulis V,Master VA,Zargar-Shoshtari K,Matin SF,Sexton WJ,Raman JD,Wood CG,Spiess PE

    更新日期:2018-04-01 00:00:00

  • Laparoscopic Partial Nephrectomy After Selective Embolization and Robot-Assisted Partial Nephrectomy: A Comparison of Short-Term Oncological and Functional Outcomes.

    abstract:BACKGROUND:Partial nephrectomy (PN) is the standard treatment for localized renal tumors. Laparoscopic PN (LPN) after selective embolization of tumor (LPNE) in a hybrid operating room has been developed to make LPN easier and safer. The aim of this study was to compare outcomes of LPNE and robot-assisted PN (RAPN). PA...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.07.005

    authors: Benoit M,Bouvier A,Panayotopoulos P,Culty T,Guillonneau B,Aube C,Azzouzi AR,Sebe P,Bigot P

    更新日期:2018-12-01 00:00:00

  • Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer.

    abstract:INTRODUCTION:Late locoregional complications in prostate cancer (PCa) affect quality of life and require medical interventions. Our objective was to compare late locoregional complications in men dying of castration-resistant PCa (CRPC) who previously received external-beam radiotherapy (EBRT) to radical prostatectomy ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.08.011

    authors: Hu J,Aprikian AG,Cury FL,Vanhuyse M,Zakaria AS,Richard PO,Perreault S,Dragomir A

    更新日期:2017-09-05 00:00:00

  • Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

    abstract:BACKGROUND:Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge. We describe the clinical characteristics and treatment of myalgia and arthralgia irAEs in CPI-treated patients with genitourinary (GU) malignancies. PATIENTS AND M...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.021

    authors: Ornstein MC,Calabrese C,Wood LS,Kirchner E,Profusek P,Allman KD,Martin A,Kontzias A,Grivas P,Garcia JA,Calabrese LH,Rini BI

    更新日期:2019-06-01 00:00:00

  • Expression of microRNAs in the urine of patients with bladder cancer.

    abstract:UNLABELLED:We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. We found that patients with bladder cancer had depressed levels of the miR-200 family, miR-192, and miR-155 in urinary sedime...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.01.001

    authors: Wang G,Chan ES,Kwan BC,Li PK,Yip SK,Szeto CC,Ng CF

    更新日期:2012-06-01 00:00:00

  • Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.

    abstract:BACKGROUND:Neoadjuvant radiotherapy (NART) for muscle-invasive bladder cancer (MIBC) is currently underused. However, the outcomes for MIBC have remained suboptimal. We investigated the relationship of NART to cause-specific mortality (CSM) and overall mortality (OM) among patients with a diagnosis of MIBC. MATERIALS ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.02.014

    authors: Diaz DA,Pollack A,Reis IM,Mahmoud O,Gonzalgo ML,Ishkanian A,Fernandez G,Manoharan M,Abramowitz MC

    更新日期:2015-08-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract:INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.006

    authors: Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期:2015-06-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract:BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.021

    authors: Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期:2020-08-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract:BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.006

    authors: Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期:2019-08-01 00:00:00

  • Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma.

    abstract:BACKGROUND:Upper urinary tract urothelial carcinoma (UUTUC) is one of the uncommon malignancies lacking of prognostic indicators. Lactate dehydrogenase (LDH) has been demonstrated to correlate with clinical outcomes in human cancers. In this study, we aimed to evaluate the prognostic implication of the preoperative LDH...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.01.003

    authors: Zhang XK,Zhang ZL,Lu X,Yang P,Cai MY,Hu WM,Yun JP,Zhou FJ,Qian CN,Cao Y

    更新日期:2016-08-01 00:00:00

  • Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

    abstract:BACKGROUND:Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itracon...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.013

    authors: Lee M,Hong H,Kim W,Zhang L,Friedlander TW,Fong L,Lin AM,Small EJ,Wei XX,Rodvelt TJ,Miralda B,Stocksdale B,Ryan CJ,Aggarwal R

    更新日期:2019-02-01 00:00:00

  • Prognostic Value of Body Mass Index According to Histologic Subtype in Nonmetastatic Renal Cell Carcinoma: A Large Cohort Analysis.

    abstract:OBJECTIVE:The objective of our study was to assess the prognostic value of body mass index (BMI) according to histologic subtype in nonmetastatic renal cell carcinoma (RCC), based on a large multicenter experience. METHODS:A total of 2769 patients with nonmetastatic RCC at the time of surgery were enrolled from 5 Kore...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2015.04.012

    authors: Lee WK,Hong SK,Lee S,Kwak C,Oh JJ,Jeong CW,Kim YJ,Kang SH,Hong SH,Byun SS

    更新日期:2015-10-01 00:00:00

  • Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

    abstract:INTRODUCTION/BACKGROUND:Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS:Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortiu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.02.009

    authors: Khambati HK,Choueiri TK,Kollmannsberger CK,North S,Bjarnason GA,Vaishampayan UN,Wood L,Knox JJ,Tan MH,MacKenzie MJ,Donskov F,Rini BI,Heng DY,International mRCC Database Consortium.

    更新日期:2014-10-01 00:00:00

  • Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

    abstract:PURPOSE:To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS:The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific su...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.05.008

    authors: Sung JM,Martin JW,Jefferson FA,Sidhom DA,Piranviseh K,Huang M,Nguyen N,Chang J,Ziogas A,Anton-Culver H,Youssef RF

    更新日期:2019-10-01 00:00:00

  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

    abstract:BACKGROUND:Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. PATIENTS AND METHODS:This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by patho...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2018.07.028

    authors: Ito K,Mikami S,Tatsugami K,Masumori N,Shinohara N,Kondo T,Nakanishi S,Nagashima Y,Eto M,Kamba T,Kuroda N,Tomita Y,Matsuyama H,Onishi T,Tsushima T,Nakazawa H,Oya M,Ozono S,Naito S,Asano T

    更新日期:2018-12-01 00:00:00

  • Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus.

    abstract::Ewing sarcoma typically presents as a skeletal-based tumor, with rare instances of peripheral primitive neuroectodermal tumor (PNET) arising in the soft tissues. Few examples of organ-based PNETs have been previously described in the literature. These tumors are exceedingly rare as a primary renal neoplasm. To our kno...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.032

    authors: Fergany AF,Dhar N,Budd GT,Skacel M,Garcia JA

    更新日期:2009-10-01 00:00:00

  • Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.024

    authors: Preisser F,Mazzone E,Knipper S,Nazzani S,Bandini M,Shariat SF,Tian Z,Saad F,Montorsi F,Zorn KC,Graefen M,Tilki D,Karakiewicz PI

    更新日期:2019-02-01 00:00:00

  • Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate whether the prior use of a novel androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy could affect the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHOD...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.07.005

    authors: Miyake H,Hara T,Ozono S,Fujisawa M

    更新日期:2017-04-01 00:00:00

  • On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.

    abstract:BACKGROUND:Preliminary studies suggested that selected drug-related toxicities of sunitinib may correlate with a better prognosis. PATIENTS AND METHODS:From January 2006 through December 2015, we retrospectively analyzed data of 145 patients with metastatic renal cell carcinoma treated with sunitinib as a first-line t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.003

    authors: Bolzacchini E,Pinotti G,Bertù L,Verusio C,Galli L,Mumoli N,Barbara C,Danova M,Bregni M,Artale S,Rossini C,Nigro O,Antonuzzo A,Derosa L,Torchio M,Barzaghi S,Ricci I,Suter M,Ballerio A,Vallini I,Dentali F

    更新日期:2020-04-01 00:00:00

  • Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

    abstract:BACKGROUND:Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with di...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.01.007

    authors: Bandini M,Pederzoli F,Madison R,Briganti A,Ross JS,Niegisch G,Yu EY,Bamias A,Agarwal N,Sridhar SS,Rosenberg JE,Bellmunt J,Pal SK,Galsky MD,Lucianò R,Gallina A,Salonia A,Montorsi F,Ali SM,Chung JH,Necchi A

    更新日期:2020-10-01 00:00:00

  • Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:Frontline treatment of metastatic castration-resistant prostate cancer (mCRPC) consists of docetaxel-based chemotherapy. The median time to progression (TTP) from chemotherapy initiation is 6 to 8 months. Ketoconazole, a nonspecific cytochrome P17 inhibitor (CYP17i), blocks adrenal androgen synthesis. Low-do...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.11.003

    authors: Gil-Bazo I,Arévalo E,Castillo A,Zudaire ME,Carranza OE,Fusco JP,Castañón E,Collado-Gómez V,López I,Gil-Aldea I

    更新日期:2013-06-01 00:00:00

  • Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration.

    abstract:INTRODUCTION:Our purpose was to: (1) assess the level of consistency between the quality-of-life (QOL) scores of men with prostate cancer for urinary/bowel/sexual bother, collected via telephone versus self-administered survey; (2) determine factors associated with variation in level of agreement; and (3) assess the ef...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.016

    authors: Sampurno F,Ruseckaite R,Millar JL,Evans SM

    更新日期:2016-08-01 00:00:00

  • Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.

    abstract:BACKGROUND:Modern radiation techniques have led to significant improvements in intracranial disease control and overall survival (OS) for metastatic renal-cell carcinoma (mRCC) patients diagnosed with brain metastases (BM). The impact of systemic therapy in patients developing mRCC BM remains undercharacterized. PATIE...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.024

    authors: Parmar A,Soliman H,Sahgal A,Bjarnason GA

    更新日期:2020-06-01 00:00:00

  • Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

    abstract:INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.007

    authors: Balakrishnan AS,Washington SL 3rd,Meng MV,Porten SP

    更新日期:2019-06-01 00:00:00

  • Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience.

    abstract:BACKGROUND:First-line PD-inhibition in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer represents a novel clinical setting, with uncertainty concerning second-line outcomes. Specifying second-line treatment and outcomes will provide guidance in this new sequence. We performed a retro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.001

    authors: Hsu MM,Xia Y,Troxel A,Delbeau D,Francese K,Leis D,Shepherd D,Balar AV

    更新日期:2020-06-01 00:00:00

  • Outcomes and tolerance of human immunodeficiency virus--positive U.S. veterans undergoing dose-escalated external beam radiotherapy for localized prostate cancer.

    abstract:INTRODUCTION:There are little data on the outcomes and tolerance, as well as the impact on the CD4 counts, of human immunodeficiency virus (HIV)-positive patients with prostate cancer who undergo high-dose external beam radiotherapy. MATERIALS AND METHODS:We identified 15 HIV-positive patients with prostate cancer who...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.07.008

    authors: Schreiber D,Chhabra A,Rineer J,Nabhani T,Katsoulakis E,Morkos R,Rotman M,Schwartz D

    更新日期:2014-04-01 00:00:00

  • New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

    abstract::Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patie...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2015.01.008

    authors: van Dodewaard-de Jong JM,Verheul HMW,Bloemendal HJ,de Klerk JMH,Carducci MA,van den Eertwegh AJM

    更新日期:2015-08-01 00:00:00